Story
TriSalus Life Sciences Stock Soars on FDA Clearance for New Drug Delivery Device
Shares of TriSalus Life Sciences (NASDAQ: TLSI) surged 29% after the company announced it received 510(k) clearance from the U.S. Food and Drug Administration for its TriNav Advance device, a new addition to its therapeutic delivery system portfolio.
FDA Greenlights TriNav Advance
The regulatory clearance allows TriSalus to market TriNav Advance, a new component of its Pressure-Enabled Drug Delivery (PEDD) platform. According to the company's announcement, the device is designed to give interventional radiologists more flexibility and precision when delivering therapeutics.
This clearance expands the company's offerings for liver-directed therapy and also supports a broader range of embolization procedures beyond the liver. TriSalus stated it plans to begin a limited market release of the new device in the coming weeks.
Enhanced Capabilities for Targeted Therapy
The TriNav Advance system is engineered to improve therapeutic delivery in complex cases. It expands the PEDD portfolio by enabling access to smaller, more distant blood vessels. Key features highlighted by TriSalus include:
Ad- Microcatheter Compatibility: It allows physicians to pair the device with a compatible microcatheter of their choice, adapting to various procedures and patient anatomies.
- Dual-Mode Functionality: The device can operate in a "telescoping mode" with a microcatheter for selective delivery or a "high-flow mode" that functions like a standard TriNav device.
Strategic Importance and Market Impact
Company executives framed the clearance as a significant step in enhancing treatment options. Mary Szela, President and CEO of TriSalus, said the device enhances the company’s portfolio "in support of the full range of liver embolization procedures."
Richard Marshall, the company's Chief Medical Officer, added that the clearance enables TriSalus to expand its impact, particularly in cases involving "tortuous anatomies." He noted it allows physicians to "optimize therapeutic delivery in difficult cases while limiting exposure to unaffected anatomical structures."
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.